Publications by authors named "Genevieve Loos"
Purpose: Brachytherapy as monotherapy is a recommended treatment option for men with low to intermediate risk prostate cancer. Local recurrence is difficult to identify. This study investigated PSMA PET/CT for recurrence after brachytherapy, as well as their subsequent management when recurrence occurred only within the prostate.
View Article and Find Full Text PDFArticle Synopsis
- Androgen deprivation therapy (ADT) combined with elective nodal radiotherapy (ENRT) shows promising long-term outcomes for men with limited prostate cancer recurrence, specifically targeting pelvic lymph nodes.
- In a trial involving 67 patients, after a median follow-up of over 6 years, a significant proportion experienced prolonged tumor control with manageable levels of toxicities.
- After 5 years, about one-third of patients remained free from biochemical relapse, highlighting ENRT's effectiveness in maintaining remission and delaying disease progression.
Article Synopsis
- The study investigates the effectiveness and safety of stereotactic body radiation therapy (SBRT) as a salvage treatment for prostate cancer recurrence after previous radiation therapy, focusing on determining the best dosing regimen.
- It included 21 patients with specific cancer characteristics, delivering either five or six doses of 6 Gy, and monitored for any severe side effects in the first 18 weeks post-treatment.
- Results showed no severe complications, and while some patients experienced mild genitourinary issues, all were alive and cancer-free during the follow-up, leading to a recommendation for the 6 × 6 Gy dosage to advance further studies.
Article Synopsis
- The study investigates the effectiveness of combining androgen deprivation therapy (ADT) with high-dose salvage radiotherapy in men with oligorecurrent pelvic node relapses of prostate cancer, aiming to extend the period without cancer progression.
- Conducted as an open-label phase II trial with 67 participants over a median follow-up of about 49 months, the results indicate strong progression-free survival rates of 81% at 2 years and 58% at 3 years, with manageable side effects reported.
- The findings suggest that this combination treatment can lead to prolonged tumor control and remission in nearly half of the patients after 3 years, indicating a promising approach for managing this challenging cancer recurrence scenario.
Article Synopsis
- - The BLINDED trial explored high-dose salvage pelvic radiation therapy for prostate cancer and assessed its early toxicity, considering the challenges of limited pelvic nodal relapse and concerns about treatment side effects.
- - A total of 67 patients participated in the study with a median age of 67.7 years; the trial found that acute urinary toxicity was experienced by 13.4% of patients, while 14.9% experienced acute digestive toxicity.
- - Overall, early toxicity rates were manageable, and quality of life assessments at one year post-treatment did not show significant deterioration among patients.
Purpose Prostate motion occurs during radiotherapy for localized prostate cancer. We evaluated the input of intraprostatic fiducials for image-guided radiation therapy and compared it with bony anatomy and skin marks. Methods Eleven patients were implanted with three fiducial markers in the prostate.
View Article and Find Full Text PDFFor pathological high-risk prostate cancer, adjuvant irradiation has shown a survival benefit. Phase III studies have highlighted that half men would face biochemical relapse and would be candidate for radiotherapy at adjuvant or salvage times. Despite at least four published international contouring guidelines from different collaborative groups, discrepancies remain for volumes, delineation, and margins to be considered in order to optimize radiotherapy planning.
View Article and Find Full Text PDF